Watson Biotech announced that the company plans to issue no more than 208 million A-shares to specific targets, Tengyun Xinwo, and the subscription amount will not exceed 2.203 billion yuan to supplement working capital. After the issuance is completed, Tengyun Xinwo will become the controlling shareholder, and Huang Tao will become the actual controller. The sale period for subscribed shares is limited to 36 months. The offering is still subject to approval by the company's shareholders' meeting, the State Administration of Market Supervision and Administration, the Shenzhen Stock Exchange, China Securities Regulatory Commission, etc., and it is uncertain whether it will be approved and when.

Watson Biotech announced that the company plans to issue no more than 208 million A-shares to specific targets, Tengyun Xinwo, and the subscription amount will not exceed 2.203 billion yuan to supplement working capital. After the issuance is completed, Tengyun Xinwo will become the controlling shareholder, and Huang Tao will become the actual controller. The sale period for subscribed shares is limited to 36 months. The offering is still subject to approval by the company's shareholders' meeting, the State Administration of Market Supervision and Administration, the Shenzhen Stock Exchange, China Securities Regulatory Commission, etc., and it is uncertain whether it will be approved and when.